Background: There is limited information on UK anaesthetists' perspectives and experiences of perioperative anaphylaxis. This baseline survey of the Sixth National Audit Project (NAP6) aimed to identify relevant departmental preparedness and practices, and individual experiences, perceptions and drug-avoidance patterns. Methods: All anaesthetists in 356 UK NHS hospitals were invited to complete an electronic survey. Results: 11 104 anaesthetists (77% crude response rate) from 341 (96%) hospitals responded. Most had immediate access to guidelines for anaphylaxis treatment (87%) and established referral pathways for investigation (82%), but a minority reported access to designated treatment packs (37%) or an anaphylaxis lead (35%). Anaesthetists reported 1734 cases of suspected perioperative anaphylaxis in 2014-5 of which 81% were referred for specialist investigation and 14% reported to the Medicines and Healthcare Products Regulatory Agency (MHRA). In their career, 76% of respondents had seen a case of perioperative anaphylaxis (1:7.25 years of practice) and 4% reported a death (1:311 years of practice), equivalent to 2.3% of events being fatal. Agents most frequently perceived to cause anaphylaxis were antibiotics, particularly penicillins, and neuromuscular blocking agents, notably rocuronium. Suxamethonium and penicillins were avoided by a higher proportion of respondents than events attributed to these drugs whereas the converse was true for atracurium and teicoplanin. Conclusions: This is the largest ever survey of anaesthetists' practices and experiences relating to perioperative anaphylaxis. It identifies gaps in preparedness and referral for further investigation and to the UK MHRA. It provides important data about drugs implicated in such events and anaesthetists' attitudes to anaphylaxis.
In 2009, the Association of Anaesthetists of Great Britain and Ireland (AAGBI) published guidance on suspected perioperative anaphylaxis. 2 This document recommended that anaesthetists refer patients to a specialist allergy centre for investigation via a locally agreed referral pathway. A recent multi-centre audit suggested that patients were not being appropriately referred for investigation. 3 In addition, the guideline advised anaesthetists to report cases of perioperative anaphylaxis to a national database, such as the UK Medicines and Healthcare Products Regulatory Agency (MHRA). It would also be expected that cases would be reported to the local hospital incident-reporting system. The perception of anaphylaxis risk is likely to influence anaesthetic practice, but little is known about which agents anaesthetists associate with being at high risk of inducing anaphylactic reactions. The limited prevalence studies available have indicated that the most frequently implicated causative drugs are antibiotics and neuromuscular blocking agents (NMBAs), 4 but little is known about what precautions anaesthetists take to avoid anaphylactic reactions and the degree, if any, to which perceived anaphylaxis risk drives clinical practice. Current perioperative practice increasingly exposes patients to chlorhexidine and newer drugs, such as sugammadex, and it is unclear how much risk these agents pose in view of emerging evidence of their association with anaphylaxis. 5 6 The use of an antibiotic 'test dose' is actively discouraged in published guidelines but the degree to which this practice persists has not previously been examined. The National Audit Projects are a series of service evaluations examining major complications related to anaesthesia, run by the Royal College of Anaesthetists (RCoA). 7 The Sixth National Audit Project (NAP6) is designed to prospectively examine quantitative and qualitative aspects of severe perioperative anaphylaxis. NAP6 comprises four components: a baseline survey of anaesthetists; a survey of specialist allergy clinics; a year-long, anonymized case-reporting phase; and lastly a survey of anaesthetic activity and exposure to potential perioperative allergens. This article describes the baseline anaesthetic survey.
The survey was undertaken in order to understand current practice and compliance with published guidance. It explores current systems for reporting, referral and management of cases of suspected perioperative anaphylaxis. The survey also examines anaesthetists' practices, perceptions of causative agents and experiences of severe perioperative anaphylaxis. The baseline survey was not intended to characterize the incidence of perioperative anaphylaxis, which is investigated by the separate case-reporting phase of NAP6.
Methods
The NAP6 project was confirmed to be a service evaluation by the National Research and Ethics Service; therefore, formal ethics approval was not required. The project was endorsed by all UK Chief Medical Officers and approved by UK statutory patient data security bodies.
All 356 participating hospitals in England, Wales and Northern Ireland appointed a volunteer local-co-ordinator (LC) anaesthetist who was responsible for reporting the number of anaesthetists within their centre, and took responsibility for advertising and disseminating the survey and recording completion rates. The survey was in the form of a hospital-based 'organizational survey' sent to the LC at each centre and an electronic questionnaire for individual anaesthetists accessible from November 5, 2015 to January 11, 2016 (see Supplementary data, Appendix 1).
Respondents were asked to provide details about departmental systems for reporting and referral of perioperative anaphylaxis and to describe their attitudes and perceptions of highrisk causative agents and of any avoidance practices. Anaesthetists were also asked to record details of suspected agents, referral and outcomes of any cases of suspected perioperative anaphylaxis (defined as a hypersensitivity reaction with severe hypotension and/or bronchospasm and/or swelling with actual or potential airway compromise and excluding minor reactions or harmless transient cutaneous flushing as an isolated feature) they had treated in the previous year. To avoid double reporting, respondents were requested to specify those cases for which they had been the most senior anaesthetist involved in the case, and separately, those cases where they had been called to assist with management.
Continuous data were described using median [Interquartile range (range)] and categorical data using 95% confidence intervals for Poisson distribution. Due to the observational nature of the survey, no statistical comparison was required.
As the response rate was high, no adjustment was made for missing data due to non-responders. Unanswered questions in the data set were highlighted as missing values rather than discarding the entire response or using imputation, which was not appropriate for this survey.
For estimating the number of new cases of perioperative anaphylaxis included in this survey we used the responses to Question 1, which referred to cases directly under the respondents' care. For all other questions, we used the reports of all cases of anaphylaxis the respondents had attended (i.e. attendances at anaphylaxis events), either as the primary anaesthetist or assisting a colleague. We used data from NAP5 in 2013 (3 598 500 anaesthetic interventions; including 2 766 600 general anaesthetics) as the denominator for the number of anaesthetic interventions delivered in the UK. 8 This was adjusted for the survey response rate, to estimate the reported incidence of perioperative anaphylaxis in the 12 months preceding the survey. It is recognized that retrospective recall is not as reliable as prospective data collection; therefore, the main focus of this survey was not to calculate incidence but rather to assess attitudes and practice ahead of the prospective data collection period of the NAP6 project.
Results
Responses were received from 341 hospitals (96% Editor's key points
• Perceptions and experiences of anaesthetists with perioperative anaphylaxis are not well documented.
• A national audit of UK anaesthetists identified that most have encountered severe anaphylaxis, but that further investigation and referral to national registries is inconsistent.
• There is a mismatch amongst UK anaesthetists in perception of risks, drugs implicated, and avoidance practices in anaphylaxis.
(SAS) doctors/trust grade doctors and 4512 trainees. The median years of anaesthetic experience was 13.0 [7.0-21.0 (0-40)], including 634 (6%) anaesthetists with less than one year of experience ( Supplementary Fig. S1 ). The crude sum for total number of years of anaesthetic experience was 154 689. A total of 11 104 anaesthetists completed the survey (77% crude response rate).
Departmental organization
A total of 9617 (87%) of anaesthetists reported having immediate access to guidelines for the treatment of anaphylaxis and 4161 (37%) reported a designated 'anaphylaxis treatment pack' being available in their department. The majority of respondents (9137, 82%) knew where to refer cases of anaphylaxis for further investigation; 7511 (68%) were aware of a specific departmental pathway and 3893 (35%) reported having a departmental lead for anaphylaxis.
Personal experiences
Respondents reported 1734 cases of suspected perioperative anaphylaxis under their direct supervision in the preceding 12 months, and that they assisted in the care of a further 2237 cases, indicating that on average 2.3 anaesthetists attend each case of perioperative anaphylaxis.
Of the combined attendances at anaphylaxis cases, 49% were known by the anaesthetist to be confirmed as anaphylaxis, 57% were managed in an intensive care or high dependency unit and 2% led to death. There was inconsistency of reporting suspected cases to relevant databases: 47% to local hospital critical incident systems and 14% to the MHRA. Referrals included 81% of cases referred for specialist allergy investigation by an anaesthetist, 10% by other clinicians and 9% were not referred for further investigation (Supplementary Table S1 ). Reasons for not referring the patient for allergy investigation were specified for 1.9% of cases: event judged not to be anaphylaxis (0.8%), the allergy was already known (0.4%), the patient refused or was not fit enough for investigation (0.2%), or that the reaction had happened too recently for the referral to have been made (0.3%).
Drugs and other agents suspected of triggering anaphylaxis
The agents suspected of triggering reactions reported over the preceding 12 months are shown in Table 1 . Antibiotics and NMBAs were each suspected of causing 40% of events and together accounted for 77% of suspected causative agents.
Risk perceptions
The agent most commonly cited by the respondents as having the highest risk of being associated with anaphylaxis was rocuronium, followed by suxamethonium and penicillin. Four per cent of respondents named a single drug, 11% named two drugs and 77% named three drugs.
Avoidance of drugs and other agents
Twenty-six per cent of anaesthetists reported trying to avoid at least one agent perioperatively due to a perception that these drugs carried a high risk of causing anaphylaxis (Supplementary  Table S2 ). Of those reporting avoidance behaviour, 62% reported avoiding one drug, 30% two drugs and 8% three drugs. The most frequently avoided agents were NMBAs (64%), i.v. fluids (12%) and antibiotics (10%). IV fluids showed the highest 'risk perception ratio' (proportion of anaesthetists reporting avoidance of agent:proportion of anaesthetists reporting a recent reaction to that agent) at 4.4 whereas chlorhexidine, suspected of causing 1:25 reactions, was infrequently reported as being avoided-risk perception ratio of 0.03.
Of those reporting avoiding an agent, 95% gave at least one reason for doing so (3725 reasons in total reported). The most common reason was avoidance due to a personal experience of anaphylaxis with the agent specified, accounting for 22% of responses (Fig. 1 ). This and local/colleague experience of anaphylaxis accounted for almost half of all causes of avoidance.
Reasons for avoidance varied between agents (Supplementary Figs S2 and S3), but personal and colleague experiences were prominent for all agents.
The influence of risk perceptions on avoidance behaviour: NMBAs and antibiotics
The NMBAs and reversal agents were perceived by anaesthetists to be most likely to cause anaphylaxis, and the individual drugs avoided by anaesthetists for such reasons are shown in Fig. 2 . The proportion of anaphylactic events in which each agent was suspected or proven (implicated) is also shown for comparison.
Rocuronium and suxamethonium were perceived to have the highest risk of causing anaphylaxis and were the NMBAs most commonly avoided by respondents whereas in actual events, rocuronium and atracurium were most frequently implicated. Suxamethonium, although perceived as high risk, was not frequently the suspected causative agent in cases reported.
A similar analysis of antibiotic anaphylaxis is shown in Fig. 3 . Penicillins were both perceived to be the most likely causative agents and avoided most often. It is notable that teicoplanin, although prominent among suspected responsible agents, was not frequently avoided.
Antibiotic test doses
Nearly one-third of anaesthetists (32%) reported routinely using a test dose when administering i.v. antibiotics, and 522 (4.7%) reported having observed an anaphylactic reaction to a test dose. 6 Career experience of anaphylaxis Seventy-six per cent of respondents reported a case of perioperative anaphylaxis during their career: the median number of cases per respondent was 2 [1-3 (0-51)] (Fig. 4) , which equates to one case per 7.25 years of practice (95% confidence interval 1:3-1:14 years). Four per cent of respondents reported a death related to perioperative anaphylaxis in their career, and anaesthetists reported a career prevalence of mortality from anaphylaxis of 498 deaths or one death per 311 years of anaesthetic practice (1:277-1:347). This equates to 2.3% of cases of suspected severe anaphylaxis being fatal.
Discussion
This is the first UK-wide investigation of perceptions among anaesthetists of perioperative anaphylaxis and adherence to guidelines for reporting and referral. The response rate of over 77% indicates that we surveyed a representative sample of UK anaesthetists. With more than 11 000 respondents, it is undoubtedly the largest ever survey on the topic and illustrates the continuing commitment of UK anaesthetists to the NAPs. The survey provides useful information about current practice ahead of two further phases of NAP6: a prospective collection of actual cases of perioperative anaphylaxis in 2015-6, and an Activity Survey recording exposure to potential perioperative allergens. The survey indicates that an anaesthetist can expect to see a case of anaphylaxis every 7.25 years of practice and a death relating to perioperative anaphylaxis every 311 years of anaesthetic practice. Whereas 76% of respondents had personal experience of anaphylaxis, more than 2500 (24%) respondents had not seen perioperative anaphylaxis during their career. The survey highlights that the vast majority of cases of perioperative anaphylaxis are not reported to national databases, and that not all patients are routinely referred for specialist allergy investigations. Uniquely, this survey shows that anaesthetists exhibit avoidance behaviours and perceive certain drugs as high risk. These perceptions may not correlate with actual risk. Unsurprisingly, the agents most frequently perceived to cause anaphylaxis remain antibiotics, particularly penicillins, and NMBAs, with rocuronium being considered highest risk.
Several that anaphylaxis guidelines are readily available in the clinical setting, with the majority of anaesthetists (87%) reporting that they had immediate access to guidelines and a similar number (82%) being confident of where to refer a patient if required. The guidelines indicate that 'the anaesthetist who gave the anaesthetic or the supervising anaesthetist is responsible for ensuring the reaction is investigated,' and 81% of cases in the previous 12 months appeared to have been referred for investigation by an anaesthetist. Regarding clinical incident reporting, only 14% were reported to the MHRA. It is possible that some cases might subsequently be reported to the MHRA by the allergy clinic, as per BSACI guidelines. 9 Nevertheless, our data suggest that estimates of rates of anaphylaxis and anaphylaxisrelated mortality inferred from MHRA data are likely to be inaccurate and significantly underestimate true prevalence. This survey highlights interesting differences in anaesthetists' perception, avoidance practices and suspected causative agents of perioperative anaphylaxis. It might be expected that the number of anaesthetists choosing to avoid a particular drug due to a perception of high risk of allergy would reflect the actual risk rate (i.e. the number of anaphylactic events expressed as a proportion of the total number of administrations of that particular drug in a large published series); however, this was not consistently observed with several drugs over or under-represented. Our results indicate that many factors influence individual perception of anaphylaxis risk and that these vary between agents. Personal and local experience appears to be an important factor in generating risk perception, being responsible for 40% of drug-avoidance behaviours.
Teicoplanin and atracurium stand out as being implicated in a greater proportion of anaphylactic reactions than would be expected from the number of anaesthetists who try to avoid these agents due to anaphylaxis risk. Teicoplanin was the suspected trigger in 28% of cases of antibiotic-related anaphylaxis, second only to penicillins (Fig. 3) . A recent case series of reactions to teicoplanin highlighted teicoplanin anaphylaxis as an emerging problem in anaesthetic allergy clinics, reporting seven definite cases from two UK centres. 3 Teicoplanin is used both as first-line prophylactic therapy for some major, particularly orthopaedic procedures, and is often the chosen therapy for those reporting penicillin allergy. The prevalence of teicoplanininduced perioperative anaphylaxis is therefore of clinical consequence and it is important that anaesthetists do not consider it a risk-free agent.
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Atracurium was suspected in 28% of cases in which an NMBA was implicated as the cause of anaphylaxis, yet only half as many respondents reported trying to avoid this drug, and the most-common reason for avoidance was concerns over nonspecific histamine release. Conversely, suxamethonium was proportionately more avoided than it was implicated in anaphylactic events, with avoidance based on published literature and the impact of other side effects. Risk perception may be influenced by both risk rate (events per use) and event rate (absolute numbers of events), and the latter will be influenced by the frequency that a drug is used. The pattern of usage of NMBAs in the UK is not currently known: the NAP6 allergen survey will provide this information and will estimate the relative incidence of perioperative anaphylaxis with specific agents. The AAGBI guidelines counsel against the use of 'test doses' when administering i.v. antibiotics. In order to be informative, diagnostic drug challenges require the controlled administration of increasing doses at intervals of 15-30 min, typically starting with 1/1000 of the therapeutic dose. 9 One-third of anaesthetists reported using a test dose, possibly believing that this practice would limit the severity of anaphylaxis. In 2002, Liberman 12 suggested that the second most common causative agent for perioperative anaphylaxis was latex, but this was reported by very few anaesthetists as a cause of concern or a causative agent for reactions in the current survey. Important progress has likely been made in the use of latex-free gloves and indwelling devices in the UK and in developing preoperative screening for identification of at-risk patients. Many hospitals now provide 'latex-free' theatre environments. Conversely, chlorhexidine anaphylaxis has become more common and could be a common 'missed diagnosis'. [13] [14] [15] [16] Our survey indicates an increasing awareness of chlorhexidine-induced reactions. It is notable that chlorhexidine was the suspected or actual cause in one in 25 cases in 2014-5, twice as many as latex. This survey, whilst not designed to provide accurate incidence data, reports 1734 cases of suspected perioperative anaphylaxis during 2014-5, an approximate incidence of 1:1556 (1:481-1:1635), which is higher than in other studies 4 17 which estimated between 1:10 000 and 1:20 000. The proportion of perioperative anaphylaxis events leading to death is one in 41 from the 12 month data and one in 43 from the career experience data. Older studies including cases from the 1970s and 1980s estimated a mortality rate of 3-9%. 18 19 However, a 2013 study 17 reported no deaths from perioperative anaphylaxis over a nine year period in Western Australia, with a mortality rate based on confidence intervals of <1.4%. The number of UK patients dying as a result of perioperative anaphylaxis is unknown and might have reduced in recent years, as guidelines have been implemented 2 and critical care outcomes have improved. 20 
Limitations and strengths
First, this is a retrospective study relying on recall, potentially over a number of years, and there are limitations with any such study. It is notable that incidence of awareness in the methodologically similar baseline survey of NAP5 were almost identical to those reported in the prospective phase of that project. 21 It is possible that in our survey anaesthetists recalled incidents beyond the previous 12 months, particularly if the anaphylactic event was very severe. It is also possible that more than one anaesthetist reported the same case due to lack of clarity over who was the primary anaesthetist. This study also asked for suspected cases of anaphylaxis, and of those only 49% were reported to have been confirmed. As many anaesthetists work in both a perioperative and critical care setting, recall may have related to cases treated in critical care rather than being truly perioperative. Despite only asking for reports of severe cases, milder cases may have been reported due to variations in the interpretation of the diagnostic criteria. For all these reasons it is quite possible that the incidences we derive from these reports may be inaccurate (overestimated) and that the actual incidence of true anaphylaxis is closer to the historical estimates. As stated above the incidence of events is not the main focus of this article. Second, the data on suspected and proven causative agents is uncertain because it is not known how many suspected events were actually anaphylaxis and how many suspected causative agents were subsequently shown to have been correctly identified: the next phase of NAP6 will shed light on these matters.
Strengths of the survey include its size and the likely generalizability of the results. The survey includes responses from almost all hospitals in the UK and more than three-quarters of all potential respondents. Our denominator for respondents is within <4% of the recent census figure of the RCoA. 22 As some 'anaesthetists' will primarily practice in pain clinics and critical care, it is likely our relevant response rate is higher than we report.
Conclusions
This is the largest ever survey of anaesthetists' experiences of and practices relating to perioperative anaphylaxis. It provides important data about the drugs that are suspected, or proven, to be involved in such events. It also highlights current practice and preparedness for perioperative anaphylaxis. The survey has identified gaps in referral for further investigation and also reporting to the MHRA, which supports the likely value of the NAP6 project in providing a more accurate registry of such events. The survey highlights a mismatch between drugs implicated in events, anaesthetist's perception of risk and avoidance practices. Of particular note, atracurium and teicoplanin are not perceived by anaesthetists to be of major concern and are rarely avoided despite both being important agents in suspected events. Chlorhexidine is implicated in a significant number of recent perioperative anaphylaxis events and appears to be a greater problem than latex.
